🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite

    Istituto Gentili S.r.l.

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Olaparib

    Fondazione Telethon ETS

    Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer

    phase 2 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL

    The George Institute

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PRT3789

    Prelude Therapeutics Inc

    non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, S095029/Sym025

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEMOZOLOMIDE, TEMOZOLOMIDE

    Fondazione Telethon ETS

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist

    Lacuna Pharma Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion., PARACETAMOL , CISPLATIN , FLUOROURACIL , -, MK-2870, CALCIUM FOLINATE , CALCIUM LEVOFOLINATE , -, MK-2870, -

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  12. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  13. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  14. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  15. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  16. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  17. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  18. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  19. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  20. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  21. LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  22. LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  23. LIBTAYO 350 mg concentrate for solution for infusion., M1774, M1774, M1774

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. LIBTAYO 350 mg concentrate for solution for infusion., THIO

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources